All Awards Company Events Invest Partners

Feb 12, 2024

Dianosic shortlisted for the “Trophées des Entreprises Alsace 2024” award

Feb 12, 2024

Dianosic x France Deeptech

Sep 08, 2023

Dianosic plans to raise EUR 10m in Series A; to seek exit sale around 2026

Jul 10, 2023

Major Funding Milestone: Dianosic raises 4.7M€ – February 2023

Jul 10, 2023

Dianosic laureate of the i-Lab 2019 innovation contest

Apr 05, 2023

Dianosic x ‌La French Care

Let's connect

Need more information?

Contact

DIANOSIC

Biotech · Paris & Strasbourg · Founded 2017

Reinventing drug delivery via the intranasal route

Dianosic develops complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.

Key highlights

Cutting-edge platform of intranasal, long-acting solid dosage forms

The DIAXX insert delivers a targeted, low dose of drug in a controlled manner for up to 12 months.

Significant potential across respiratory and neurological indications

Chronic allergic rhinitis (8M), chronic rhinosinusitis (5M) and CNS diseases via Nose-to-Brain delivery (Schizophrenia, Parkinson — 23M) represent large adressable markets.

Solving a critical adherence challenge

50% of patients do not adhere to their medications across therapeutic areas. Our "insert and forget" approach guarantees 100% adherence.

€7M raised in 2025 — led by Aptar Pharma

Series A round with Aptar (Global drug delivery leader), Noshaq, Capital Grand Est and Finovam Gestion to accelerate clinical development.

A complementary team

In-house Pharma and Medtech expertise supported by a Scientific Board composed of world-renowned experts.

contact@dianosic.com